Trial Profile
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 01 Jul 2019 Results of a post hoc analysis evaluating the effect of semaglutide on levels of alanine aminotransferases and C reactive protein in subjects enrolled in two clinical trials of semaglutide treatment for obesity or type 2 diabetes published in the Alimentary Pharmacology and Therapeutics
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases